The Safety and Efficacy of Laparoscopic Surgical Staging and Debulking of Apparent Advanced Stage Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

被引:49
|
作者
Nezhat, Farr R. [1 ]
DeNoble, Shaghayegh M. [1 ]
Liu, Connie S. [2 ]
Cho, Jennifer E. [1 ]
Brown, Douglas N. [1 ]
Chuang, Linus [3 ]
Gretz, Herbert [3 ]
Saharia, Prakash [4 ]
机构
[1] Columbia Univ, Dept Obstet & Gynecol, Div Gynecol Oncol & Minimally Invas Surg, St Lukes Roosevelt Med Ctr, New York, NY 10019 USA
[2] NYU, Langone Med Ctr, Dept Obstet & Gynecol, New York, NY USA
[3] Mt Sinai Med Ctr, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, New York, NY 10029 USA
[4] Winthrop Univ Hosp, Dept Gen Surg, Mineola, NY 11501 USA
关键词
Laparoscopy; Ovarian Cancer; Cytoreduction; IV EPITHELIAL OVARIAN; CYTOREDUCTIVE SURGERY; SURVIVAL; CARCINOMA; MANAGEMENT; LAPAROTOMY; IMPACT; RATES;
D O I
10.4293/108680810X12785289143990
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives: To describe our experience with laparoscopic primary or interval tumor debulking in patients with presumed advanced ovarian, fallopian tube, or peritoneal cancers. Methods: This is a retrospective analysis of a prospective case series. Women with presumed advanced (FIGO stage IIC or greater) ovarian, fallopian tube, or primary peritoneal cancers deemed appropriate candidates for laparoscopic debulking by the primary surgeon(s) were recruited. Results: The study comprised 32 patients who underwent laparoscopic evaluation. Seventeen underwent total laparoscopic primary or interval cytoreduction, with 88.2% optimal cytoreduction. Eleven underwent diagnostic laparoscopy and conversion to laparotomy for cytoreduction, with 72.7% optimal cytoreduction. Four patients had biopsies, limited cytoreduction, or both. In the laparoscopy group, 9 patients have no evidence of disease (NED), 6 are alive with disease (AWD), and 2 have died of disease (DOD), with mean follow-up time of 19.7 months. In the laparotomy group, 3 patients are NED, 5 are AWD, and 3 are DOD, with mean follow-up of 25.8 months. Estimated blood loss and length of hospital stay were less for the laparoscopy group (P=0.008 and P=0.03), while operating time and complication rates were not different. Median time to recurrence was 31.7 months for the laparoscopy group and 21.5 months for the laparotomy group (P=0.3). Conclusions: Laparoscopy can be used for diagnosis, triage, and debulking of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer and is technically feasible in a well-selected population.
引用
收藏
页码:155 / 168
页数:14
相关论文
共 50 条
  • [21] Serous ovarian, fallopian tube and primary peritoneal cancers: A comparative epidemiological analysis
    Jordan, Susan J.
    Green, Adle C.
    Whiteman, David C.
    Moore, Suzanne P.
    Bain, Christopher J.
    Gertig, Dorota M.
    Webb, Penelope M.
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (07) : 1598 - 1603
  • [22] Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome
    Nezhat, Farr R.
    Ezzati, Mohammad
    Chuang, Linus
    Shamshirsaz, Alireza A.
    Rahaman, Jamal
    Gretz, Herb
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 200 (01) : 83.e1 - 83.e6
  • [23] Laparoscopic Assessment to Determine the Likelihood of Achieving Optimal Cytoreduction in Patients Undergoing Primary Debulking Surgery for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Andikyan, Vaagn
    Kim, Annie
    Gretz, Herbert F., III
    Zakashansky, Konstantin
    Prasad-Hayes, Monica
    Beddoe, Ann-Marie
    Dottino, Peter
    Mandeli, John
    Chuang, Linus
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (10): : 938 - 942
  • [24] Comment on "Primary Chemotherapy for Inoperable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without Delayed Debulking Surgery"
    Barton, Desmond P. J.
    Naik, Rajan
    Pomel, Christophe
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (07) : 1104 - 1105
  • [25] RE: "Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers"
    Fagotti, A.
    Vizzielli, G.
    Scambia, G.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (01) : 201 - 201
  • [26] Characteristics and Management of Diaphragm Involvement in Patients With Primary Advanced-Stage Ovarian, Fallopian Tube, or Peritoneal Cancer
    Einenkel, Jens
    Ott, Rudof
    Handzel, Romy
    Braumann, Ulf-Dietrich
    Horn, Lars-Christian
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (07) : 1288 - 1297
  • [27] Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
    Swetzig, Wendy M.
    Lurain, John Robert
    Berry, Emily
    Pineda, Mario Javier
    Shahabi, Shohreh
    Perry, La Toya
    Neubauer, Nikki Lynn
    Nieves-Neira, Wilberto
    Schink, Julian C.
    Schiller, Alissa
    Novak, Karen
    Anderson, Nancy Jean
    Burdett, Kirsten Bell
    Strohl, Anna Everett
    Kocherginsky, Masha
    Matei, Daniela
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] The new FIGO staging system for ovarian, fallopian tube and primary peritoneal cancer - 2014 update
    Zalewski, Kamil
    Misiek, Marcin
    Gozdz, Stanislaw
    Bidzinski, Mariusz
    ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 (03): : 129 - 134
  • [29] SAFETY AND EFFICACY OF NIRAPARIB IN PATIENTS WITH ADVANCED, RELAPSED, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (QUADRA)
    Moore, K.
    Rimel, B. J.
    Achour, H.
    Naumov, G.
    Agarwal, S.
    Balser, J.
    Monk, B. J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 784 - 784
  • [30] Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy
    Esselen, Katharine M.
    Rodriguez, Noah
    Growdon, Whitfield
    Krasner, Carolyn
    Horowitz, Neil S.
    Campos, Susana
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 51 - 54